Indeed, genetic profiling of GBM biopsies has revealed aberrant expression of several potential therapeutic targets, including a number of RTKs (EphA3, EGFR, VEGF, PDGFR, and MET), however, there has been varied and limited clinical success in the use of inhibitors of these targets as anti-cancer therapies. Here, PDGFRB is linked to cancer.